Clinical Trials List
2020-07-20 - 2029-05-26
Phase III
Recruiting8
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 黃文聰 Division of Hematology & Oncology
- 林建良 Division of Hematology & Oncology
- 陳彥勳 Division of Hematology & Oncology
- 林正耀 Division of Hematology & Oncology
- Shang-Wen Chen Division of Hematology & Oncology
- 蕭聖諺 Division of Hematology & Oncology
- 高婉真 Division of Hematology & Oncology
- 陳昭勳 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- CHENG-HONG TSAI Division of Hematology & Oncology
- - - Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ting-An Lin Division of Hematology & Oncology
- 蔡淳光 Division of Hematology & Oncology
- Hao-Yuan Wang Division of Hematology & Oncology
- Chia-Jen Liu Division of Hematology & Oncology
- Po-Shen Ko Division of Hematology & Oncology
- 沈書慧 Division of Hematology & Oncology
- Yao-Chung Liu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ming-Chung Kao Division of Hematology & Oncology
- 高小雯 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chi-Ching Chen Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Tzu-Ting Chen Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Jeng-Shiun Du Division of Hematology & Oncology
- 王閔宏 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
330 participants
